NCT07334080 ECC4703 Food Effect and Relative Bioavailability Study in Healthy Adult Participants
| NCT ID | NCT07334080 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Eccogene |
| Condition | Metabolic Dysfunction-Associated Steatohepatitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 72 participants |
| Start Date | 2026-01-07 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 72 participants in total. It began in 2026-01-07 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a Phase I, open-label, randomized, single-dose, 2-part study designed to evaluate the food effect and relative bioavailability of ECC4703 in healthy adult participants.
Eligibility Criteria
Inclusion Criteria: * Healthy male and female participants * Age of 18 to 65 years * BMI of 18.0 to 32.0 kg/m2 with a minimum body weight of 50.0 kg (110 lb) for males and 45.0 kg (99 lb) for females. * Female participants of childbearing potential must have negative serum pregnancy test at screening and a negative serum or urine pregnancy test prior to the first dose of study drug; use at least 1 highly effective method of contraception (e.g., hormonal contraception, intrauterine device, bilateral tubal occlusion, or vasectomized partner with confirmed success) during the study and for at least 90 days after the last dose of study drug; and refrain from egg donation or fertility treatments during the same period. * Female participants who are postmenopausal, confirmed by FSH test, or surgically sterile, confirmed by medical documentation, or agree to practice true abstinence * Male participants agree to use contraception, or agree to practice true abstinence * Not taking any medication within 14 days (or at least 5 half-lives whichever is longer) prior to Day 1 dosing, with the exception of stable-dose contraception, stable-dose hormonal replacement therapy, paracetamol at up to 2 g/day; or other medication, which in the opinion of the investigator and sponsor will not interfere with study assessments. * No clinically significant findings in physical examination, 12-lead electrocardiogram (ECG), vital sign measurements, clinical laboratory evaluations, concomitant medications, or medical/psychiatric history * Able to understand and sign and date informed consent Exclusion Criteria: * Females who are pregnant, planning to become pregnant, or breastfeeding during the study or within 90 days after the study. * Concomitant participation in any investigational study of any nature * Blood loss of ≥470 mL for non-physiological reasons (i.e., trauma, blood collection, blood donation) within 3 months prior to the first dose of study drug, plasma donation within 2 weeks prior to the first dose, platelet donation within 6 weeks prior to the first dose, or plans to donate blood during this study or within 1 month after the last dose of study drug. * Clinically relevant acute or chronic medical conditions or diseases of the cardiovascular, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic, psychiatric, immune or dermatologic systems * Significant allergic reaction to active ingredients or excipients of the study drug * Regularly uses tobacco or nicotine products, including e-cigarettes (\>5 times per week) or has stopped using regular tobacco or nicotine products within the past 2 months. * Unwilling to abstain from alcohol-containing products and/or xanthine/caffeine-containing products, including any food and beverages, within 48 hours prior to admission to the CRU on Day -1. * Unwilling to abstain from grapefruit, grapefruit juice, and Seville oranges from 7 days prior to check-in on Day -1 until after their final follow-up visit. * Unable to refrain from the use of any over-the-counter medications, prescription medications, nutritional supplements, or herbal medicines during the study, except for stable-dose contraception, stable-dose hormonal replacement therapy, paracetamol at up to 2 g/day; or other medication, which in the opinion of the investigator and sponsor will not interfere with study assessments. * Any clinically significant abnormal findings in the participant's physical examination, laboratory tests, pregnancy test, urine drug screen, alcohol test, or medical history which in the opinion of the Investigator would prevent the participants from participating in the study. * Has had clinically significant interventional therapies and/or hospitalization (surgery, paracentesis, etc.) within 6 months prior to the study, or plans to have any surgeries during the duration of the study.
Contact & Investigator
Eccogene Clinical Trials
STUDY DIRECTOR
Eccogene
Frequently Asked Questions
Who can join the NCT07334080 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Metabolic Dysfunction-Associated Steatohepatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07334080 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07334080 currently recruiting?
Yes, NCT07334080 is actively recruiting participants. Contact the research team at contact@eccogene.com for enrollment information.
Where is the NCT07334080 trial being conducted?
This trial is being conducted at Adelaide, Australia.
Who is sponsoring the NCT07334080 clinical trial?
NCT07334080 is sponsored by Eccogene. The principal investigator is Eccogene Clinical Trials at Eccogene. The trial plans to enroll 72 participants.